Intellectual Property: Last chance for Europe's biotech pioneers

Nuala Moran

Erythropoietin is a hot candidate biogenerics companies (picture courtesy Flamel Technologies)

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

The pioneers of the biotech industry get a last chance to defend their products against imitators at a meeting in Paris today and tomorrow (8 - 9 December). The European Medicines Agency (EMEA) has called the meeting as the final stage in a five-year consultation process to establish rules for the...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.